Phosphodiesterase type III inhibitor, cilostazol, inhibits colon cancer cell motility

Clinical and Experimental Metastasis

Volumn 17, Issue 6, 1999, Pages 525-530

  Murata, Kohei ^a,b   Kameyama, Masao ^a   Fukui, Fumiyo ^a   Ohigashi, Hiroaki ^a   Hiratsuka, Masahiro ^a   Sasaki, Yo ^a   Kabuto, Toshiyuki ^a   Mukai, Mutsuko ^a   Mammoto, Tadanori ^a   Akedo, Hitoshi ^a   Ishikawa, Osamu ^a   Imaoka, Shingi ^b  

^a Department of Surgical Oncology ^*  (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Cell motility; Cilostazol; Colon cancer; Invasion; Phosphodiesterase type III

Indexed keywords

ANTIMETASTATIC AGENT; CILOSTAZOL;

ARTICLE; CELL CULTURE; CELL INVASION; CELL MOTILITY; COLON CANCER; DRUG MECHANISM; HUMAN; HUMAN CELL; METASTASIS INHIBITION;

ANIMALS; CATTLE; CELL MOVEMENT; COLONIC NEOPLASMS; HUMANS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; TETRAZOLES; TUMOR CELLS, CULTURED;

EID: 0033511150     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006626529536     Document Type: Article

References (23)

1. 1. Midgley R, Kerr D. Colorectal cancer. Lancet 1999; 353: 391-9.
2. 2. Imamura F, Horai T, Mukui M et al. Induction of in vitro tumor cell invasion of cellular monolayers by lysophosphatidic acid or phospholipase D. Biochem Biophys Res Commun 1993; 193: 497-503.
3. 3. Mukai M, Imamura F, Ayaki M et al. Inhibition of tumor invasion and metastasis by a novel lysophosphatidic acid (cyclic LPA). Int J Cancer 1999; 81: 918-22.
4. 4. Beavo JA, Conti M, Heaslip RJ. Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol 1994; 46: 399-405.
5. 5. Sorkin EM, Markham A. Cilostazol. Drugs Aging 1999; 14: 63-71; discussion 72-3.
6. 6. Welch DR, Lobl TJ, Seftor EA et al. Use of the Membrane Invasion Culture System (MICS) as a screen for anti-invasive agents. Int J Cancer 1989; 43: 449-57.
7. 7. Albrecht-Buehler G. The phagokinetic tracks of 3T3 cells. Cell 1977; 11: 395-404.
8. 8. Takaishi K, Kikuchi A, Kuroda S et al. Involvement of rho p21 and its inhibitory GDP/GTP exchange protein (rho GDI) in cell motility. Mol Cell Biol 1993; 13: 72-9.
9. 9. Akedo H, Shinkai K, Mukai M et al. Interaction of rat ascites hepatoma cells with cultured mesothelial cell layers: a model for tumor invasion. Cancer Res 1986; 46: 2416-22.
10. 10. Dawson DL, Cutler BS, Meissner MH, Strandness DE, Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98: 678-86.
11. 11. Ikeda Y, Matsumata T, Takenaka K et al. Effects of doxorubicin and/or cilostazol on cancer cells during liver regeneration after two-thirds hepatectomy in rats. Oncology 1998; 55: 354-6.
12. 12. Tanaka K, Iwamoto Y, Ito Y et al. Cyclic AMP-regulated synthesis of the tissue inhibitors of metalloproteinases suppresses the invasive potential of the human fibrosarcoma cell line HT1080. Cancer Res 1995; 55: 2927-35.
13. 13. Mokashi S, Delikatny SJ, Orr FW. Relationships between chemotaxis, chemotactic modulators, and cyclic nucleotide levels in tumor cells. Cancer Res 1983; 43: 1980-3.
14. 14. Morton DM, Tchao R. Regulation of motility and cytoskeletal organization of rat bladder carcinoma cells by cyclic AMP. Cell Motil Cytoskeleton 1994; 29: 375-82.
15. 15. Bianco C, Tortlora G, Baldassarre G et al. 8-Chloro-cyclic AMP inhibits autocrine and angiogenic growth factor production in human colorectal and breast cancer. Clin Cancer Res 1997; 3: 439-48.
16. 16. Murata J, Ayukawa K, Ogasawara M et al. Induction of autocrine factor inhibiting cell motility from murine BI6-BL6 melanoma cells by alpha-melanocyte stimulating hormone. Int J Cancer 1999; 80: 889-95.
17. 17. Ridgway AA, De Vouge MW, Mukherjee BB. Dibutyryl cAMP inhibits expression of transformation-related properties in Kirsten murine sarcoma virus transformed Balb/c-3T3 cells despite continued presence of p21v-Ki-ras. Biochem Cell Biol 1988; 66: 54-65.
18. 18. Lee J, Choi YH, Nguyen P et al. Cyclic AMP induces inhibition of cyclin A expression and growth arrest in human hepatoma cells. Biochim Biophys Acta 1999; 1449: 261-8.
19. 19. Takahashi S, Oida K, Fujiwara R et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 1992; 20: 900-6.
20. 20. Matousovic K, Grande JP, Chini CC et al. Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppress mitogenesis of rat mesangial cells. J Clin Invest 1995; 96: 401-10.
21. 21. Hinoda Y, Saito T, Takahashi H et al. Induction of nonspecific cross-reacting antigen mRNA by interferon-gamma and anti-fibronectin receptor antibody in colon cancer cells. J Gastroenterol 1997; 32: 200-5.
22. 22. Taylor R, Lee TD, Hoskin DW. Adhesion of tumoricidal eosinophils to MCA-38 colon adenocarcinoma cells involves protein tyrosine kinase activation and is diminished by elevated cyclic AMP in the effector cell. Int J Oncol 1998; 13: 1305-11.
23. 23. Tortora G, di Isernia G, Sandomenico C et al. Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. Cancer Res 1997; 57: 5107-11.